Combination chemotherapy of ranimustine, doxorubicine, and dexamethasone for relapsing multiple myeloma--a pilot study.
Twenty patients with relapsing myeloma were treated with combination chemotherapy of ranimustine, doxorubicine, and dexamethasone (RAD) between July 1996 and March 2000. Of the 19 evaluable patients, 5 (26.3%) achieved partial response after the first round of RAD therapy and 10 (52.6%) achieved partial response after the second round of RAD therapy. Of 10 evaluable patients who had previously received high-dose dexamethasone therapy including VAD therapy, 2 (20%) achieved partial response after the first round of RAD therapy and 3 (30%) achieved partial response after the second round of RAD therapy. The median survival was 10.5 months and the progression-free survival was 9.3 months. Patients who responded to RAD therapy had a survival rate at 43 months of 59.3%. Toxicity and adverse events during RAD therapy were tolerable. This pilot study demonstrated that RAD therapy is useful for the treatment o frefractory myeloma.
Murakami
Hirokazu
H
School of Health Sciences, Faculty of Medicine, Gunma University, Maebashi, Gunma 371-8511, Japan. hmura@health.gunmau.ac.jp
Yamane
Arito
A
Sawamura
Morio
M
Matsumoto
Morio
M
Murayaman
Kayoko
K
Shimano
Shunichi
S
Jinbo
Takahiro
T
Yokohama
Akihiko
A
Uchiumi
Hideki
H
Handa
Hiroshi
H
Matsushima
Takafumi
T
Tsukamoto
Norifumi
N
Morita
Kimio
K
Karasawa
Masamitsu
M
Ogawara
Hatsue
H
Nojima
Yoshihisa
Y
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003907:Dexamethasone / Q000009:adverse effects / Q000627:therapeutic use*; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality; D009607:Nitrosourea Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D010865:Pilot Projects
D009607:Nitrosourea Compounds; D003907:Dexamethasone; D004317:Doxorubicin; C020766:ranimustine